Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Sees Significant Drop in Short Interest

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) was the target of a large drop in short interest in August. As of August 31st, there was short interest totaling 5,300 shares, a drop of 67.7% from the August 15th total of 16,400 shares. Based on an average daily volume of 156,800 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.1% of the shares of the stock are sold short. Approximately 0.1% of the shares of the stock are sold short. Based on an average daily volume of 156,800 shares, the days-to-cover ratio is currently 0.0 days.

Hepion Pharmaceuticals Price Performance

HEPA opened at $0.06 on Friday. The company’s 50 day simple moving average is $0.06 and its two-hundred day simple moving average is $0.63. Hepion Pharmaceuticals has a 1-year low of $0.03 and a 1-year high of $0.08. The firm has a market capitalization of $634,642.50, a price-to-earnings ratio of -0.01 and a beta of 1.52.

Hepion Pharmaceuticals Company Profile

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.